Team USA Paralympian alpine skier Kelsey O’Driscoll says there aren’t a lot of words to express what being in Cortina means ...

To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts ...

For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease flares in COPD.

As part of its 2026 home health strategy, home health and hospice provider CommonSpirit Health at Home is moving care upstream and plotting a thoughtful ...

Medication non-adherence among people with chronic obstructive pulmonary disease (COPD) is a result of lack of affordability and lack of knowledge about medications, among other factors, according ...

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

European Commission backs first ultra‑long‑acting biologic for respiratory disease GSK has secured European Commission approval for Exdensur (depemokimab) to treat severe asthma with type 2 ...

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...